Press release
Irritable Bowel Syndrome (IBS) market is expected to more than double, reaching USD 11.3 billion by 2034
Irritable Bowel Syndrome (IBS) market
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71363
The IBS patient pool is expected to rise steadily through 2034, supported by lifestyle changes, dietary factors, stress-related triggers, and the increasing prevalence of gastrointestinal disorders worldwide. Growing recognition of IBS as a serious health concern is fueling investments in patient care, treatment innovation, and digital health solutions.
Market Overview
• Market Size (2024): USD 5 billion
• Forecast (2034): USD 11.3 billion
• CAGR (2025-2034): ~8%
• Key Growth Drivers: Rising diagnosis rates, growing healthcare awareness, lifestyle-related risk factors, and expanding therapeutic portfolios.
• Key Challenges: Lack of curative therapies, misdiagnosis, symptom overlap with other GI disorders.
• Leading Players: AbbVie, Takeda, Ironwood Pharmaceuticals, Bausch Health, Astellas Pharma, Novartis, AstraZeneca, Johnson & Johnson.
With the launch of novel medications (e.g., linaclotide, eluxadoline, rifaximin) and rising use of probiotics and dietary interventions, the IBS market is evolving into a multi-faceted ecosystem that combines drug therapies, lifestyle management, and digital monitoring tools.
Segmentation Analysis
By Type of IBS
• IBS with Constipation (IBS-C)
• IBS with Diarrhea (IBS-D)
• Mixed IBS (IBS-M)
• Unclassified IBS (IBS-U)
By Therapy
• Prescription Medications (linaclotide, eluxadoline, rifaximin, lubiprostone, alosetron)
• Over-the-Counter (OTC) Medications
• Probiotics and Nutraceuticals
• Dietary & Lifestyle Interventions
• Digital Health Apps & Behavioral Therapy
By Diagnosis
• Symptom-based Assessment (Rome IV criteria)
• Laboratory Testing
• Endoscopy & Imaging
• Biomarker-based Diagnostics
By End Use
• Hospitals
• Gastroenterology Clinics
• Ambulatory Care Centers
• Homecare / Digital Health Platforms
Summary: While IBS-D and IBS-C dominate patient prevalence, the fastest-growing therapeutic segment is digital health apps and probiotics, as patients increasingly demand non-invasive, long-term solutions.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71363/irritable-bowel-syndrome-ibs-patient-pool-analysis-market
Regional Analysis
• North America: Largest market due to high prevalence, strong adoption of novel therapies, and robust healthcare expenditure. The U.S. dominates with advanced diagnostics and patient-centric digital solutions.
• Europe: Strong focus on lifestyle and dietary interventions, alongside adoption of targeted therapies. Key countries include Germany, the UK, France, and Italy.
• Asia-Pacific: Fastest-growing region, with rising urbanization, dietary shifts, and stress-related GI conditions. China, Japan, and India drive regional growth.
• Middle East & Africa: Emerging market with gradual adoption of IBS diagnostics and treatments, limited by awareness gaps and healthcare access.
• Latin America: Brazil and Mexico lead in IBS treatment adoption, supported by improving healthcare systems and rising GI disease prevalence.
Summary: North America and Europe dominate today, but Asia-Pacific is projected to post the fastest CAGR through 2034, driven by urban lifestyles, stress factors, and growing healthcare accessibility.
Market Dynamics
Key Growth Drivers
• Increasing prevalence of gastrointestinal and stress-related disorders.
• Growing awareness and diagnosis, reducing underreporting of IBS cases.
• Rising adoption of targeted prescription therapies and probiotics.
• Expanding digital health tools for remote IBS management.
Key Challenges
• Symptom overlap with other GI diseases, leading to misdiagnosis.
• High reliance on lifestyle modification rather than curative therapies.
• Limited treatment adherence due to side effects of long-term drug use.
Latest Trends
• Precision medicine approaches using microbiome analysis for personalized care.
• Growing role of digital therapeutics and AI-driven monitoring apps.
• Increased clinical trials exploring microbiome-based therapies and novel drug classes.
• Stronger emphasis on holistic treatment, combining diet, stress management, and behavioral therapy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71363
Competitor Analysis
Major Players
• AbbVie - Key player with eluxadoline (Viberzi) for IBS-D.
• Takeda - Strong GI portfolio, focusing on IBS pipeline therapies.
• Ironwood Pharmaceuticals - Market leader with linaclotide (Linzess).
• Bausch Health - Active in GI treatments and OTC medications.
• Astellas Pharma - Expanding R&D in gastrointestinal disorders.
• Novartis & AstraZeneca - Exploring precision medicine approaches.
• Johnson & Johnson - Investing in probiotics and microbiome research.
Summary: The competitive landscape is moderately consolidated, with Ironwood and AbbVie leading in prescription therapies, while J&J and Novartis push into microbiome and holistic treatment strategies.
Conclusion
The IBS patient pool analysis market is expanding steadily, reflecting the combined effects of rising prevalence, growing awareness, and a more diverse treatment landscape. With projections indicating strong growth through 2034, IBS management is shifting from symptomatic relief to personalized, long-term care models.
Key Takeaways:
• IBS prevalence is increasing globally, with significant economic and quality-of-life impacts.
• Prescription therapies dominate today, but probiotics and digital health solutions are rapidly gaining traction.
• North America and Europe lead the market, while Asia-Pacific offers the fastest growth potential.
• Companies focusing on microbiome research, AI-driven diagnostics, and holistic care will capture emerging opportunities.
The coming decade promises improved patient outcomes, more accurate diagnostics, and integrated treatment solutions, making IBS one of the most dynamic areas in gastrointestinal healthcare.
This report is also available in the following languages : Japanese (過敏性腸症候群(IBS)患者プール分析市場), Korean (과민성 대장 증후군(IBS) 환자 풀 분석 시장), Chinese (肠易激综合征(IBS)患者群体分析市场), French (Analyse du marché des patients atteints du syndrome du côlon irritable (SCI)), German (Marktanalyse für Patientenpools mit Reizdarmsyndrom (IBS)), and Italian (Analisi del mercato dei pazienti affetti da sindrome dell'intestino irritabile (IBS)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71363/irritable-bowel-syndrome-ibs-patient-pool-analysis-market#request-a-sample
Our More Reports:
Staphylococcus aureus Bacteremia Market
https://exactitudeconsultancy.com/reports/71753/staphylococcus-aureus-bacteremia-market
Acute Bacterial Prostatitis Market
https://exactitudeconsultancy.com/reports/71755/acute-bacterial-prostatitis-market
Allergic Bronchopulmonary Aspergillosis Market
https://exactitudeconsultancy.com/reports/71757/allergic-bronchopulmonary-aspergillosis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome (IBS) market is expected to more than double, reaching USD 11.3 billion by 2034 here
News-ID: 4165221 • Views: …
More Releases from Exactitude Consultancy
Adult mitochondrial epilepsy presentation
Mitochondrial epilepsy is a rare but severe neurological condition caused by genetic mutations that impair mitochondrial function, disrupting cellular energy production in the brain. Patients often present with seizures, developmental delays, and neurodegeneration. It is closely associated with broader mitochondrial diseases such as MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) and Leigh syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72869
Due to its rarity and complexity, treatment options…
Is Peptide Therapeutic the Way of the Future for Targeted Therapy?
Peptide therapeutics are a rapidly growing class of drugs that occupy a space between small molecules and biologics. Derived from natural or synthetic amino acid sequences, peptide-based therapies offer high specificity, low toxicity, and strong efficacy across a wide range of diseases. They are increasingly used in oncology, metabolic disorders, cardiovascular diseases, infectious diseases, and rare genetic conditions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72871
The market is witnessing…
SSG Hospital launches an AI-powered oncology chatbot
The global AI in Oncology Market is rapidly emerging as one of the most transformative frontiers in healthcare, combining advanced machine learning, big data analytics, and clinical expertise to fight cancer. With oncology representing one of the most complex medical domains, artificial intelligence (AI) is reshaping how clinicians detect, diagnose, and treat cancer. AI is accelerating drug discovery, enhancing diagnostic imaging, enabling personalized treatment recommendations, and improving patient monitoring. As…
Orion and Abilita Therapeutics Announce Research Partnership to Create Next-Gene …
The global Next-Generation Antibody Therapeutics Market is experiencing rapid growth as pharmaceutical and biotechnology companies push the boundaries of antibody engineering to deliver safer, more effective, and highly targeted therapies. Unlike conventional monoclonal antibodies, next-generation formats-such as bispecific antibodies, antibody-drug conjugates (ADCs), antibody fragments, and engineered scaffolds-offer enhanced specificity, improved pharmacokinetics, and novel mechanisms of action. These innovations are revolutionizing treatment landscapes in oncology, autoimmune disorders, infectious diseases, and rare…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…
